Publications by authors named "Pascal Furet"

Claim this Profile
H
Harnessing Glutamine-117 Plasticity toward Structure-Based Identification of Triazole IL-17 Inhibitors.
Matthias R Bauer, Juraj Velcicky, Alban Goetz, Pascal Furet, Pierre Nimsgern

J Med Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Exploration of 1,3,4-Oxadiazole and α-Fluoroacrylate Containing IL-17 Inhibitors.
Juraj Velcicky, Matthias R Bauer, Achim Schlapbach, Guillaume Lapointe, Arndt Meyer, Pascal Furet

J Med Chem· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Emilie A Chapeau, Laurent Sansregret, Giorgio G Galli, Patrick Chène, Markus Wartmann, Pascal Furet

Nat Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Emilie A Chapeau, Laurent Sansregret, Giorgio G Galli, Patrick Chène, Markus Wartmann, Pascal Furet

Nat Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissecting the Interaction Fingerprints and Binding Affinity of BYL719 Analogs Targeting PI3Kα.
Sepehr Dehghani-Ghahnaviyeh, Cihan Soylu, Pascal Furet, Camilo Velez-Vega

J Phys Chem B· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes.
Simone Bonazzi, Audrey Gray, Noel M Thomsen, Jonathan Biag, Nancy Labbe-Giguere, Pascal Furet

J Med Chem· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP-TEAD Protein-Protein Interaction Inhibitors.
Holger Sellner, Emilie Chapeau, Pascal Furet, Markus Voegtle, Bahaa Salem

ChemMedChem· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging Advanced In Silico Techniques in Early Drug Discovery: A Study of Potent Small-Molecule YAP-TEAD PPI Disruptors.
Ernest Awoonor-Williams, Callum J Dickson, Pascal Furet, Andrei A Golosov, Viktor Hornak

J Chem Inf Model· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition.
Pascal Furet, Vincent Bordas, Mickaël Le Douget, Bahaa Salem, Yannick Mesrouze

ChemMedChem· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.
Robin A Fairhurst, Pascal Furet, Patricia Imbach-Weese, Frédéric Stauffer, Heinrich Rueeger

J Med Chem· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p53 dynamics vary between tissues and are linked with radiation sensitivity.
Jacob Stewart-Ornstein, Yoshiko Iwamoto, Miles A Miller, Mark A Prytyskach, Stephane Ferretti, Pascal Furet

Nat Commun· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.
Robin A Fairhurst, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Pascal Furet

J Med Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to "2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4".
Thomas Knoepfel, Pascal Furet, Robert Mah, Nicole Buschmann, Catherine Leblanc

ACS Med Chem Lett· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new perspective on the interaction between the Vg/VGLL1-3 proteins and the TEAD transcription factors.
Yannick Mesrouze, Gustavo Aguilar, Fedir Bokhovchuk, Typhaine Martin, Clara Delaunay, Pascal Furet

Sci Rep· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of FAM181A and FAM181B as new interactors with the TEAD transcription factors.
Fedir Bokhovchuk, Yannick Mesrouze, Clara Delaunay, Typhaine Martin, Frédéric Villard, Pascal Furet

Protein Sci· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
Andreas Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm, Robin A Fairhurst, Pascal Furet

Mol Cancer Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence.
Pascal Furet, Bahaa Salem, Yannick Mesrouze, Tobias Schmelzle, Ian Lewis

Bioorg Med Chem Lett· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes.
Joerg Kallen, Aude Izaac, Suzanne Chau, Emmanuelle Wirth, Joseph Schoepfer, Pascal Furet

ChemMedChem· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy.
Fedir Bokhovchuk, Yannick Mesrouze, Aude Izaac, Marco Meyerhofer, Catherine Zimmermann, Pascal Furet

FEBS J· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang, Huai-Xiang Hao, Angela Tam, Pascal Furet

Clin Cancer Res· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.
Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, Jeanette Fuchs, Emilie A Chapeau, Pascal Furet

Cancer Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.
Andrea Vaupel, Philipp Holzer, Stephane Ferretti, Vito Guagnano, Joerg Kallen, Pascal Furet

Bioorg Med Chem Lett· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptation of the bound intrinsically disordered protein YAP to mutations at the YAP:TEAD interface.
Yannick Mesrouze, Fedir Bokhovchuk, Aude Izaac, Marco Meyerhofer, Catherine Zimmermann, Pascal Furet

Protein Sci· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, Silvia Buonamici, Simona Cotesta, Pascal Furet

J Med Chem· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.
Paul W Manley, Giorgio Caravatti, Pascal Furet, Johannes Roesel, Phi Tran

Biochemistry· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis